SODIUM DITIOCARB AS ADJUVANT IMMUNOTHERAPY FOR HIGH-RISK BREAST-CANCER - A RANDOMIZED STUDY
SODIUM DITIOCARB AS ADJUVANT IMMUNOTHERAPY FOR HIGH-RISK BREAST-CANCER - A RANDOMIZED STUDY
复制标题
DOI：
10.1007/bf01877380
复制
发表时间：
1993-01-01
期刊：
影响因子：
--
通讯作者：
OBERLING, F
中科院分区：
文献类型：
--
作者：
DUFOUR, P;LANG, JM;OBERLING, F
64例非转移性高危乳腺癌患者随机参加双盲试验，以双硫卡钠（DDC）与安慰剂进行辅助免疫治疗。所有患者均接受了既往手术（根据Patey进行的腰椎切除术），然后接受了辅助FAC化疗+/- DDC。中位随访5年，我们观察到DDC组6例复发和5例死亡;对照组13例复发和t2死亡。6年时，DDC组的总生存率为81%，而DDC组为55%。DDC组的无病生存率（DFS）为76%，而DDC组为55%。DDC联合化疗和局部治疗可以改善这种高危乳腺癌亚组的生存率，并可能改善DFS。
Sixty-four patients with non metastatic high risk breast cancer were randomized in a double blind trial of adjuvant immunotherapy with sodium ditiocarb (DDC) versus placebo. All patients underwent prior surgery (mammectomy according to Patey) then adjuvant FAC chemotherapy +/- DDC. With a median follow-up of 5 years we observed 6 relapses and 5 deaths in DDC group; 13 relapses and t2 deaths in control group. At 6 years, overall survival is 81% in DDC group versus 55%. Disease free survival (DFS) is 76% in DDC group versus 55%. DDC associated to chemotherapy and locoregional treatment can improve survival and probably DFS in this high risk breast cancer subgroup.